Skip to content Skip to footer

Chief Scientific Officer, Bexson Biomedical

Brief info

Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. He was one of the first MDs in U.S. administering and documenting ketamine for depression in the clinic, and is a world recognized speaker and expert in the neurobiology and clinical use of ketamine. As Chief Scientific Officer at Bexson Biomedical, he heads development of a pipeline of novel racemic and enantiomer specific ketamine formulations for subcutaneous delivery with a disposable patch pump. Bexson's new ketamine delivery platform is designed for potential application treating numerous pain and mental health conditions.

Leave a comment

Tickets Are Now On Sale
Get Tickets Now